Latest news with #2025BloomBurton&Co.HealthcareInvestorConference
National Post
29-04-2025
- Business
- National Post
Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
Article content WALTHAM, Mass. & MONTREAL — Ventus Therapeutics, a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and neurological disorders, today announced that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference, being held May 5-6 in Toronto. Dr. Bigal will be presenting on Tuesday, May 6, at 1:30 p.m. ET. Article content Article content Ventus Therapeutics is a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and neurological disorders. Using its proprietary drug discovery platform, ReSOLVE ®, the company has established a robust pipeline, including two wholly-owned programs. VENT-03 is a first-in-class, oral cGAS inhibitor expected to enter Phase 2 development for lupus in 2025. VENT-02 is a best-in-class, brain-penetrant, oral NLRP3 inhibitor in Phase 2 for Parkinson's disease, and is expected to enter Phase 2 development for osteoarthritis in obese patients later in 2025. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted, oral NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S. For more information, please visit and engage with Ventus on LinkedIn. Article content Article content Article content Article content Article content Contacts Article content Article content
Cision Canada
29-04-2025
- Business
- Cision Canada
LSL PHARMA GROUP INC. ANNOUNCES ITS PARTICIPATION IN THE "2025 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE"
BOUCHERVILLE, QC, April 29, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (TSXV: (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, announced today it will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference. Mr. Roberge, President and CEO, will make a presentation on May 5 at 10:30 EST, and will be available for one-on-one meetings throughout the conference. A live and recorded webcast of the LSL Pharma presentation will be available on the "Information for Investors" section of LSL Pharma corporate website or at the following link: For more information on the "2025 Bloom Burton & Co. Healthcare Investor Conference" or to register, please follow this link. ABOUT THE CONFERENCE The Bloom Burton & Co. Healthcare Investor Conference brings together American, Canadian and international investors interested in the latest developments in Canadian healthcare companies. Participants will have the opportunity to obtain up-to-date information on leading Canadian public and private companies, through presentations and private meetings. ABOUT LSL PHARMA GROUP INC. LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and marketing of high-quality sterile ophthalmic pharmaceuticals, as well as cosmetic, pharmaceutical and natural health products in solid, semi-solid and liquid forms. For further information, please visit Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has reviewed and does not accept responsibility for the adequacy or accuracy of this release. SOURCE Groupe LSL PHARMA INC.
